H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 33.15 DKK 0.61%
Market Cap: 33B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

Net Margin
H Lundbeck A/S

12.5%
Current
12%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.5%
=
Net Income
2.7B
/
Revenue
21.4B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DK
H Lundbeck A/S
CSE:HLUN A
32.9B DKK
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
17%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
19%
CH
Roche Holding AG
SIX:ROG
199.4B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
161.4B GBP
13%
CH
Novartis AG
SIX:NOVN
170.9B CHF
35%
US
Pfizer Inc
NYSE:PFE
149.4B USD
7%
Country DK
Market Cap 32.9B DKK
Net Margin
13%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 729.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.8T DKK
Net Margin
35%
Country US
Market Cap 347.8B USD
Net Margin
17%
Country US
Market Cap 248.3B USD
Net Margin
19%
Country CH
Market Cap 199.4B CHF
Net Margin
20%
Country UK
Market Cap 161.4B GBP
Net Margin
13%
Country CH
Market Cap 170.9B CHF
Net Margin
35%
Country US
Market Cap 149.4B USD
Net Margin
7%
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
32.9B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 50%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.5%
=
Net Income
2.7B
/
Revenue
21.4B
What is the Net Margin of H Lundbeck A/S?

Based on H Lundbeck A/S's most recent financial statements, the company has Net Margin of 12.5%.